{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:16:34Z","timestamp":1794813394254,"version":"4.9.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40265-021-01550-w","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T10:03:07Z","timestamp":1624010587000},"page":"1229-1233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Loncastuximab Tesirine: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"1550_CR1","unstructured":"ADC Therapeutics SA. ZYNLONTA\u2122 (loncastuximab tesirine-lpyl); US prescribing information. 2021. https:\/\/adctherapeutics.com\/. Accessed 2 Jun 2021."},{"issue":"5","key":"1550_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/annonc\/mdy092","volume":"29","author":"S Makita","year":"2018","unstructured":"Makita S, Tobinai K. Antibody therapy targeting CD19 for B-cell non-Hodgkin\u2019s lymphoma. Ann Oncol. 2018;29(5):1086\u20139.","journal-title":"Ann Oncol"},{"key":"1550_CR3","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma [media release]. 23 Apr 2021. https:\/\/www.fda.gov\/."},{"key":"1550_CR4","unstructured":"ADC Therapeutics SA. ADC Therapeutics and Overland Pharmaceuticals announce formation of Overland ADCT BioPharma to develop and commercialize Lonca and other ADCs for hematologic and solid tumor indications in Greater China and Singapore [media release]. 14 Dec 2020. http:\/\/www.adctherapeutics.com."},{"key":"1550_CR5","unstructured":"ADC Therapeutics SA. ADC Therapeutics and Freenome enter biomarker development collaboration [media release]. 26 Aug 2019. www.adctherapeutics.com."},{"key":"1550_CR6","unstructured":"Auven Therapeutics. Auven Therapeutics announces AstraZenecas MedImmune acquires antibody-drug conjugate company Spirogen and invests in ADC Therapeutics [media release]. 15 Oct 2013. http:\/\/www.auventx.com."},{"issue":"10","key":"1550_CR7","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","volume":"131","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi F, Corbett S, Adams L, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131(10):1094\u2013105.","journal-title":"Blood"},{"issue":"19","key":"1550_CR8","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","volume":"137","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634\u201345.","journal-title":"Blood"},{"key":"1550_CR9","unstructured":"Depaus J, Wagner-Johnston ND, Zinzani PL, et al. Interim results of loncastuximab tesirine combined with ibrutinib in diffuse large B-cell lymphoma or mantle cell lymphoma (LOTIS-3) [abstract no. 2099 and presentation]. In: ASH 2020."},{"issue":"3","key":"1550_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/bloodadvances.2019000767","volume":"4","author":"N Jain","year":"2020","unstructured":"Jain N, Stock W, Zeidan A, et al. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020;4(3):449\u201357.","journal-title":"Blood Adv"},{"key":"1550_CR11","unstructured":"US National Institutes of Health. ClinicalTrials.gov. 2021. https:\/\/clinicaltrials.gov\/. Accessed 2 Jun 2021."},{"key":"1550_CR12","unstructured":"ADC Therapeutics. ADC Therapeutics reports first quarter 2021 financial results and provides business updates [media release]. 6 May 2021. https:\/\/www.adctherapeutics.com\/."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01550-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01550-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01550-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T12:26:48Z","timestamp":1626352008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01550-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1550"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01550-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]},"assertion":[{"value":"18 June 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}